GSA Capital Partners LLP Makes New $878,000 Investment in Liquidia Corporation $LQDA

GSA Capital Partners LLP purchased a new position in Liquidia Corporation (NASDAQ:LQDA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 38,621 shares of the company’s stock, valued at approximately $878,000.

A number of other hedge funds have also bought and sold shares of LQDA. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia in the third quarter valued at about $30,000. NewEdge Advisors LLC bought a new position in shares of Liquidia in the 2nd quarter worth approximately $25,000. Steward Partners Investment Advisory LLC boosted its holdings in shares of Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after buying an additional 1,200 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the period. Finally, RMR Capital Management LLC bought a new stake in Liquidia during the third quarter valued at approximately $212,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on LQDA shares. HC Wainwright boosted their price objective on shares of Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 13th. Jefferies Financial Group raised their target price on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price target on shares of Liquidia in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Liquidia Stock Performance

NASDAQ LQDA opened at $33.59 on Friday. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The company has a market cap of $2.92 billion, a P/E ratio of -23.33, a P/E/G ratio of 0.98 and a beta of 0.46. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The business’s 50 day moving average price is $37.56 and its 200-day moving average price is $30.23.

Insider Activity

In other Liquidia news, CEO Roger Jeffs sold 66,610 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $2,493,212.30. Following the completion of the sale, the chief executive officer directly owned 1,037,528 shares of the company’s stock, valued at $38,834,673.04. The trade was a 6.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Dana Boyle sold 1,580 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $41.65, for a total value of $65,807.00. Following the transaction, the chief accounting officer owned 178,848 shares in the company, valued at $7,449,019.20. The trade was a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 216,820 shares of company stock valued at $8,102,685. Insiders own 26.50% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).